Kairos Pharma Ltd (KAPA) Short-Term Debt to Equity

Graphic logo of Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA) is developing oncology drugs, aiming for licensing fees from pharma behemoths through its patents. Simultaneously, the company is implementing energy efficiency and waste filtration in its laboratories. The market trend for share prices with the 0.00 metric reflects debt dynamics. In the future, data analysis automation and robotic compound screening will accelerate growth, reducing drug development timelines.

KAPA - Kairos Pharma Ltd Short-Term Debt to Equity Ratio over the range 09/17/2024 - 11/01/2026

Financial and market metric breakdowns for Kairos Pharma Inc (KAPA)

- stock quotes and analyst forecast:
Stock Price Kairos Pharma Ltd|KAPA - Analyst Consensus Forecast
- market capitalization details:
Market Value Kairos Pharma Limited|KAPA - Business Value
- balance sheet equity data:
Book Value per Share Kairos Pharma|KAPA - Company Net Assets|Market Capitalization to Book Value Ratio kairospharma.com|KAPA - Company Assets
- business debt structure and liquidity details:
Debt to Equity Kairos Pharma Ltd|KAPA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Kairos Pharma Ltd|KAPA - Aggregate Debt Obligations|Debts to Book Capitalization Kairos Pharma Limited|KAPA - Company Long-Term Liabilities|Company Current Liabilities Kairos Pharma|Quick Liquidity kairospharma.com
- earnings and market ratios statistics:
KAPA - Final Profit
Fundamental valuation:Kairos Pharma
Signature product of kairospharma.com

For the research-oriented Kairos Pharma Ltd (KAPA) with its flexible R&D structure, the balance between short-term liabilities and equity determines the ability to maintain research autonomy without liquidity risk. By analyzing the trend of short-term loans relative to equity, an investor assesses the proportion of urgent borrowings within the capital structure: an increase in this metric warns of default risks, while minimal values confirm the conservative stability of the business.

Competitors of Kairos Pharma Ltd

Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|UroGen Pharma Ltd (URGN) - Short-Term Debt to Equity Ratio|BCAX: Short-Term Debt to Capital|Current Liabilities to Capital Personalis Genomics (PSNL)|Short-Term Debt to Equity Erasca, Inc.|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CADL (Candel Therapeutics, Inc.)|ARAY - Short-Term Debt to Equity Ratio|SLS: Short-Term Debt to Equity Ratio|ACTU - Short-Term Debt to Capital|Citius Oncology (CTOR) - Short-Term Debt to Equity|TuHURA Biosciences - Ratio of Short-Term Indebtedness to Capital|TARA (Protara) - Short-Term Debt to Capital|Current Liabilities to Capital Fate Pharma FATE|Short-Term Debt to Equity Aadi Bioscience Inc (WHWK)|Short-Term Debt to Capital tscan.com (TCRX)|Short-Term Debt to Capital CSBR (Champions Oncology, Inc.)|Short-Term Debt to Capital XBiotech Inc XBIT|CEL-SCI Corp - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient OS Therapies, Inc. OSTX|Radiopharm Theranostics (RADX) - Short-Term Debt to Equity|Artiva Biotherapeutics - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Adlai Nortye Ltd|Current Liabilities to Capital Veru Inc VERU|Short-Term Debt to Equity Tempest Tx (TPST)|Short-Term Debt to Capital Coefficient xiliotx.com|Renovaro - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital MURA|OKUR - Short-Term Debt to Equity|Current Liabilities to Equity GDTC|CRIS: Short-Term Debt to Capital|Apollomics - Ratio of Short-Term Indebtedness to Capital|THAR (Tharimmune, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Advanced Biomed Corp|Short-Term Debt to Equity Genprex (GNPX)|CLDI (calidibio.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sunshine Biopharma SBFM|XBIO - Short-Term Debt to Equity Ratio|Salarius Pharmaceuticals - Short-Term Debt to Capital|PPBT - Short-Term Debt to Capital|AONC (aoncology.com) - Short-Term Debt to Equity Ratio|BeiGene Ltd. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Checkpoint Therapeutics, Inc|Short-Term Debt to Equity ELEV|Short-Term Debt to Equity Ratio ICAD (iCAD, Inc.)|Short-Term Loans to Capital Ratio IKNA|Short-Term Debt to Capital NTBL (Notable Labs)|VIRX: Short-Term Debt to Capital Ratio|MOR - Short-Term Debt to Equity|NAYA - Short-Term Debt to Capital|AAPGV: Short-Term Debt to Capital